Core Viewpoint - The Hong Kong stock market for innovative pharmaceuticals has seen a significant rebound in 2025, with over 30 companies doubling their stock prices, indicating a potential revaluation of the sector after a prolonged downturn [1][2]. Market Trends - Since the beginning of 2025, the innovative drug sector has become the best-performing segment in the Hong Kong stock market, with companies like 3SBio and Innovent Biologics experiencing substantial market capitalization increases [1]. - The Hang Seng Innovation Drug Index has rebounded to 50% of its historical high, reflecting a recovery from a 76% decline since July 2021 [2][3]. - 82% of the 18A listed pharmaceutical companies in Hong Kong have seen their stock prices rise in 2025 [3]. Investment Activity - There has been a surge in initial public offerings (IPOs) in the innovative drug sector, with 18 companies applying to list on the Hong Kong Stock Exchange since the beginning of the year, including a record 7 in just the first half of June [1]. - The trend of License-out transactions has gained traction, with significant upfront payments, such as 3SBio's $1.25 billion deal, boosting market confidence [4][5]. Capital Flow - There is a noticeable increase in both domestic and international capital flowing into the Hong Kong innovative drug market, with net inflows exceeding HKD 40 billion since 2025 [10]. - The proportion of mainland funds in the Hang Seng Innovation Drug Index has risen from 18% to 22.6% since the beginning of the year [10]. Future Outlook - The market sentiment has shifted positively, with industry leaders discussing expansion and acquisitions rather than survival strategies [3][4]. - Despite the optimism, some investors remain cautious, noting that the current enthusiasm may not be sustainable without systemic support for the industry [11][12].

Core Viewpoint - Junshi Bioscience announced a placement of new H-shares, leading to a significant drop in stock prices for both A-shares and H-shares [1][2]. Group 1: Share Placement Details - The company will issue 41,000,000 new H-shares at a price of HKD 25.35 per share, which represents approximately 18.70% of the total issued H-shares and 4.16% of the total issued shares as of the announcement date [1][2]. - The total expected proceeds from the placement are approximately HKD 1,039 million, with a net amount of about HKD 1,026 million after deducting commissions and estimated expenses [2]. - The net amount raised per H-share after expenses is expected to be around HKD 25.02 [2]. Group 2: Use of Proceeds - The company plans to allocate 70% of the net proceeds from the placement to innovative drug research and development, including specific projects such as JS207, JS212, and JS213 [2]. - The remaining 30% of the net proceeds will be used for general corporate purposes, including working capital [2]. Group 3: Shareholder Impact and Authorization - The placement will not require shareholder approval as it falls under the general authorization allowing the board to issue up to 197,137,974 shares, which is 20% of the total issued shares as of June 21, 2024 [3]. - It is anticipated that no placement participants will become major shareholders following the transaction [3]. Group 4: Financial Performance - In the first quarter of 2025, the company reported revenue of CNY 5.01 billion, a year-on-year increase of 31.46%, while the net loss attributable to shareholders was CNY 2.35 billion, an improvement from CNY 2.83 billion in the same period last year [8]. - The company has consistently reported net losses over the years, with significant losses recorded from 2016 to 2024 [7].

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Core Viewpoint - Junshi Bioscience plans to raise approximately HKD 1.039 billion through the placement of 41 million new H-shares at a price of HKD 25.35 per share, which represents an 11.52% discount to the closing price on June 12 [1] Group 1: Fundraising and Use of Proceeds - The company intends to allocate 70% of the raised funds for innovative drug development, focusing on dual-specific antibodies such as JS207 (PD-1/VEGF), JS212 (EGFR/HER3), and JS213 (PD-1/IL-2) [1] - The remaining funds will be used to supplement working capital [1] - Junshi Bioscience previously announced an investment of CNY 767 million in the PD-1/VEGF dual antibody (JS207) [1] Group 2: Clinical Development and Market Position - JS207 is currently in Phase II clinical trials, with plans to conduct key clinical trials for lung cancer, breast cancer, liver cancer, colorectal cancer, and other advanced solid tumors [1] - Junshi Bioscience, established in December 2012, was the first domestic company to receive approval for a PD-1 monoclonal antibody, but its product, Toripalimab, has faced stiff competition from later entrants [4] - Toripalimab remains the company's leading product, generating CNY 1.501 billion in domestic sales in 2024, accounting for 77% of total revenue of CNY 1.948 billion [4] Group 3: Financial Performance and Market Trends - Despite not yet achieving profitability, the company's losses have significantly narrowed in 2024, with Q1 revenue and net loss reported at CNY 500 million and CNY 235 million, respectively [4] - The PD-1/VEGF dual antibody field has gained traction, with significant competitive developments, including a head-to-head trial where a competitor's product outperformed the leading PD-1 drug [5] - The innovative drug sector has seen a strong performance in the A-share market, with a 12.72% increase in May and a total increase of over 22% from April to June [6]

证券代码：688180 证券简称：君实生物 公告编号：临 2025-034 上海君实生物医药科技股份有限公司 关于根据一般授权配售新 H 股的公告 | 2023年年度股东 大会 | 指 | 本公司于2024年6月21日举行的2023年年度股东大会 | | --- | --- | --- | | A股 | 指 | 本公司股本中每股面值人民币1.00元的普通股，以人民 | | | | 币买卖并于上海证券交易所上市 | | A股股东 | 指 | A股持有人 | | 董事会 | 指 | 本公司董事会 | | 营业日 | 指 | 香港银行开放办理一般银行业务的任何日子（不包括 | | | | 星期六、星期日及香港公众假期） | | 交割 | 指 | 配售事项的交割 | | 交割日期 | 指 | 交割的日期，即2025年6月20日（或本公司与独家配售 | | | | 代理书面协议的其他有关时间及/或日期） | | 本公司 | 指 | 上海君实生物医药科技股份有限公司，一间于中国成 | | | | 立的股份有限公司，其H股及A股分别于香港联交所主 | | | | 板及上海证券交易所上市交易 | | 关连人士 | 指 | 具 ...

文件显示：君实生物寻求高达1.04亿美元的配售。 君实生物拟以每股25-26港元配售3140万股。 ...

A股生物制品板块午后异动拉升，派林生物涨停，荣昌生物、长春高新、君实生物、百普赛斯、诺诚健 华等跟涨。 ...

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

Group 1 - Xinyu Securities clarified that it has not received any written or verbal information regarding a merger with Huafu Securities, and there are no significant undisclosed matters related to the merger [2] - Keda Li plans to jointly invest with Weichuang Electric and others to establish Suzhou Yizhi Intelligent Drive Technology Co., Ltd. with a registered capital of 50 million yuan, where Keda Li will contribute 15 million yuan for a 30% stake [2] - Shuangliang Energy signed a sales contract worth 450 million yuan for a green hydrogen production system, which is expected to positively impact the company's assets and net profit [3] Group 2 - Hesheng New Materials intends to invest 250 million yuan in Yizhi Electronics, acquiring a 10% stake in a company specializing in ARM server processor chips [4] - Junshi Biosciences received acceptance for a clinical trial application for JT118 injection, a vaccine aimed at preventing monkeypox virus infection [5] - Tinci Materials plans to invest approximately 2.8 million USD to build an integrated production base for electrolytes and raw materials in Morocco, with an annual production capacity of 150,000 tons [6] Group 3 - Beikong Technology's static and rolling P/E ratios are higher than the industry average, indicating potential overvaluation [7] - Qingdao Bank announced that Qingdao Guoxin Group intends to increase its stake in the bank to a maximum of 19.99% through its subsidiaries, pending regulatory approval [8] - Xiamen Airport reported an 8.34% year-on-year increase in passenger throughput for May, while Hubei Energy's power generation increased by 2.27% [9]

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].